

02/25/00

jc584 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket

GI 5229FWC-AV1

Total Pages

39

First Named Inventor or Application Identifier

John P. Leonard

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. Specification [Total Pages 27]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

3. Drawing(s) (35 USC 113) [Total Sheets 6]

4. Oath or Declaration [Total Pages 6]
 a. Unsigned (original or copy)
 b. Copy from a prior application (37 CFR 1.63(d))
 (for continuation/divisional with Box 17 completed)
 [Note Box 5 below]
 i. DELETION OF INVENTOR(S)
 Signed statement attached deleting
 inventor(s) named in the prior application,
 See 37 CFR 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (useable if Box 4b is checked)
 The entire disclosure of the prior application, from which
 a copy of the oath or declaration is supplied under Box
 4b, is considered as being part of the disclosure of the
 accompanying application and is hereby incorporated by
 reference therein.

6. Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(If applicable, all necessary)
 a. Computer Readable Copy
 b. Paper Copy
 c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & documents(s))

9. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)

10. English Translation Document (if applicable)

11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. Small Entity Statement filed in prior application,
Statement(s) Status still proper and desired

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Other: . . . Inventor Data Sheet
.....

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 08/560,943

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or Correspondence address below

NAME	Suzanne A. Sprunger, Ph.D.				
	American Home Products Corporation				
ADDRESS	Patent & Trademark Department - 2B				
	One Campus Drive				
CITY	Parsippany	STATE	NH	ZIP CODE	07054
COUNTRY	U.S.A.	TELEPHONE	(617) 665-8284		FAX (617) 876-5851

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the correspondence marked below is being deposited with the U.S. Postal Service "Express Mail PO to Addressee" service under 37 CFR 1.10 on February 25, 2000, Express Mail label no. ~~EE632046037U3~~, in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or printed name	Suzanne A. Sprunger, Ph.D.		
Signature	<i>Suzanne A. Sprunger</i>	Date	February 25, 2000

jc584 U.S. PTO
09/512701
02/25/00

FEE TRANSMITTAL

TOTAL AMOUNT OF PAYMENT (\$ 690

Complete if Known

Application Number	1020
Filing Date	February 25, 2000
First Named Inventor	John Leonard et al.
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	GI 5229FWC-DIV1

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 07-1060

Deposit Account Name Genetics Institute, Inc.

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Charge the Issue Fee Set in 37 CFR 1.18 at the mailing of the Notice of Allowance, 37 CFR 1.311 (b)

2. Payment Enclosed:

Check Money Order Other

FEE CALCULATION (fees effective 10/01/97)

1. FILING FEE

Large Entity	Small Entity				
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	690	220	395	Utility filing fee	690
106	330	206	165	Design filing fee	
107	540	207	270	Plant filing fee	
108	790	208	395	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$ 690

2. CLAIMS

Total Claims	Extra -20	Fee from below	Fee Paid	
Independent Claims	1 - 3	0 X 78	0	
Multiple Dependent Claims		X	=	
103	18	203	11	Claims in excess of 20
102	78	202	41	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
109	82	209	41	Reissue independent claims over original patent
110	22	210	11	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0

3. ADDITIONAL FEES

Large Entity	Small Entity					
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	
105	130	205	65	Surcharge - late filing fee or oath		
127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
139	130	139	130	Non-English specification		
147	2,520	147	2,520	For filing a request for reexamination		
112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
115	110	215	55	Extension for response within first month		
116	400	216	200	Extension for response within second month		
117	950	217	475	Extension for response within third month		
118	1,510	218	755	Extension for response within fourth month		
119	310	219	155	Notice of Appeal		
120	310	220	155	Filing a brief in support of an appeal		
121	270	221	135	Request for oral hearing		
138	1,510	138	1,510	Petition to institute a public use proceeding		
140	110	240	55	Petition to revive unavoidably abandoned application		
141	1,320	241	660	Petition to revive unintentionally abandoned application		
142	1,320	242	660	Utility issue fee (or reissue)		
143	450	243	225	Design issue fee		
144	670	244	335	Plant issue fee		
122	130	122	130	Petitions to the Commissioner		
123	50	123	50	Petitions related to provisional applications		
126	240	126	240	Submission of Information Disclosure Stmt		
581	40	581	40	Recording each patent assignment per property (times number of properties)		
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))		
149	790	249	395	For each additional invention to be examined (37 CFR 1.129 (b))		

Other fee (specify) _____

Other fee (specify) _____

SUBTOTAL (3) (\$ 0

* Reduced by Basic Filing Fee Paid

SUBMITTED BY


Typed or Printed Name	Suzanne A. Sprunger, Ph.D.			Complete (if applicable)
Reg. Number	41,323			

Signature		Date	February 25, 2000	Deposit Account User ID	07-1060
-----------	---	------	-------------------	-------------------------	---------

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the correspondence marked below is being deposited with the U.S. Postal Service "Express Mail PO to Addressee" service under 37 CFR 1.10 on February 25, 2000 Express Mail label no. ~~EL00001662710~~, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

~~EE 632096637-U S~~


Typed or printed name	Suzanne A. Sprunger, Ph.D.			Date	February 25, 2000
Signature					

Dated: February 25, 2000

Respectfully submitted,



Suzanne A. Sprunger, Ph.D.
Reg. No. 41,323
Attorney of Record
American Home Products Corporation
Patent & Trademark Department - 2B
One Campus Drive
Parsippany, NJ 07054
Telephone: (617) 665-8284
Facsimile: (617) 876-5851

EE632646637US
"Express Mail" mailing label number:
Date of Deposit 25 FEB. 2000
I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service
under 37 CFR 1.10 on the date indicated above
and is addressed to the Assistant Commissioner
For Patents, Washington, D.C. 20231


2000-02-25 10:25:00

Exhibit A
U.S. Ser. No. 09/XXX,XXX (Divisional of 08/560,943)
Pending Claims as Presented January 2000

24 (NEW). A method for treating rheumatoid arthritis in a human subject, said method comprising administering to said subject a therapeutically effective amount of an IL-12 antagonist that binds IL-12, wherein said antagonist is selected from the group consisting of an antibody immunoreactive with IL-12 and an antibody fragment immunoreactive with IL-12.

25 (NEW). The method of claim 24 wherein said antagonist is administered in a dose of about 0.05 to about 25 mg/kg.

26 (NEW). The method of claim 24 wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

27 (NEW). The method of claim 24 wherein said antagonist is an antibody immunoreactive with IL-12.

28 (NEW). The method of claim 24 wherein said antagonist is an antibody fragment reactive with IL-12.

DRAFT - FEB 2000